CORALVILLE, Iowa, Feb. 22, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) announced that it has developed a new method of cryopreservation of human stem cells. This new method takes advantage of the superior thermal conductivity of Vivakor's VivaThermic vials and reduces the overall cryopreservation and thawing recovery times. Select leading stem cell researchers and institutions have begun testing this new method. To accommodate the response to this major advancement in cryopreservation, additional researchers and institutions interested in testing this new method of preservation are invited to contact Vivakor directly to determine if they qualify for participation in the Company's suitability studies utilizing the new VivaThermic 2.0 cryovials.
Vivakor Chairman Matt Nicosia stated: "The ability to dramatically impact this critical area of research is a matter of great pride for all of us at Vivakor. The fact that this will have a major impact on both our own research and the market for our new vials is extremely exciting."
To learn more about these vials, please visit www.vivathermic.com. If you are a research professional or have professional inquiries regarding the 2.0 cryovials, please visit www.vivathermic.com/contact-us.
About Vivakor
Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.